Porton B, Ferreira A, DeLisi LE, Kao HT (2004) A rare polymorphism affects a mitogen-activated protein kinase site in synapsin III: possible relationship to schizophrenia. Biol Psychiatry 55, 118-25 14732590

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S470-p - SYN3 (human) ▲

Modsite: PQGQQPLsPQsGsPQ SwissProt Entrez-Gene Orthologous residues SYN3 (human): S470‑p, SYN3 (mouse): S469‑p, SYN3 (rat): S469‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'brain, embryonic', 'neuron, hippocampal'-'brain, embryonic' Cellular systems studied:  primary cultured cells, tissue Species studied:  mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE ERK1 (mouse) KINASE CDK1 (mouse) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neurotrophin-3 increase PD98059 neurotrophin-3 inhibit treatment-induced increase